Login to Your Account

Financings Roundup

Oncolytics Stock Offering Gets $32M to Push Reolysin

By Randy Osborne
Staff Writer

Thursday, February 21, 2013
Oncolytics Biotech Inc.'s broad cancer program with the reovirus variant Reolysin gained $32 million worth of gross-proceeds firepower with the pricing of a public stock sale of 8 million shares at $4 each.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription